Screening and management of long-term consequences of myeloma and its treatment
Affecting multiple areas of the body where bone marrow is active, myeloma life expectancy rates have improved steadily over the past two decades.
Essential facts
Each year in the UK approximately 4,900 people are diagnosed with myeloma, a type of cancer which develops from the plasma cells in the bone marrow. In myeloma, plasma cells become abnormal, multiply uncontrollably and stop releasing the normal range of antibodies.
Myeloma affects multiple places in the body where bone marrow is normally active, such as the bones of the spine, skull, pelvis, rib cage and limbs. Myeloma is a relapsing-remitting cancer, with periods of stable remission.
What’s new?
Life expectancy rates for patients with myeloma have improved considerably over the past two decades.
...Want to read more?
Unlock full access to RCNi Plus today
Save over 50% on your first three months:
- Customisable clinical dashboard featuring 200+ topics
- Unlimited online access to all 10 RCNi Journals including Cancer Nursing Practice
- RCNi Learning featuring 180+ RCN accredited learning modules
- NMC-compliant RCNi Portfolio to build evidence for revalidation
- Personalised newsletters tailored to your interests
This article is not available as part of an institutional subscription. Why is this?
